High-level amplification at 17q23 leads to coordinated overexpression of multiple adjacent genes in breast cancer

被引:36
作者
Parssinen, J.
Kuukasjarvi, T.
Karhu, R.
Kallioniemi, A. [1 ]
机构
[1] Tampere Univ Hosp, Inst Med Technol, Canc Genet Lab, FIN-33014 Tampere, Finland
[2] Univ Tampere, FIN-33014 Tampere, Finland
[3] Tampere Univ Hosp, Dept Pathol, FIN-33520 Tampere, Finland
基金
芬兰科学院;
关键词
breast cancer; gene amplification; gene expression;
D O I
10.1038/sj.bjc.6603692
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Increased copy numbers of 17q23 chromosomal region have been shown to occur in different tumour types and to be associated with tumour progression and with poor prognosis. Several genes have earlier been proposed as potential oncogenes at this region largely on the grounds of cell lines studies. In this study, we performed a systematic gene expression survey on 26 primary breast tumours with known 17q23 amplification status by quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR). The 17q23 amplicon is restricted to an similar to 5MB region in breast cancer and contains 29 known genes. Our survey revealed a statistically significant (P < 0.01) difference between the high level and no amplification groups in a set of eleven genes whereas no difference between the moderate and the non-amplified tumour groups were observed. Interestingly, these 11 genes were located adjacent to one another within a 1.56 Mb core region in which all except one of the genes were overexpressed. These data suggest that only high-level amplification at the 17q23 amplicon core leads to elevated gene expression in breast cancer. Moreover, our results highlight the fact that 17q23 amplicon carries multiple candidate genes and that this may be a more common event in gene amplification than previously thought.
引用
收藏
页码:1258 / 1264
页数:7
相关论文
共 57 条
[1]   High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays [J].
Andersen, CL ;
Monni, O ;
Wagner, U ;
Kononen, J ;
Bärlund, M ;
Bucher, C ;
Haas, P ;
Nocito, A ;
Bissig, H ;
Sauter, G ;
Kallioniemi, A .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (01) :73-79
[2]  
Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO
[3]  
2-Z
[4]  
Bärlund M, 2000, CANCER RES, V60, P5340
[5]   Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis [J].
Bärlund, M ;
Forozan, F ;
Kononen, J ;
Bubendorf, L ;
Chen, YD ;
Bittner, ML ;
Torhorst, J ;
Haas, P ;
Bucher, C ;
Sauter, G ;
Kallioniemi, OP ;
Kallioniemi, A .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (15) :1252-1259
[6]  
Baselga J, 1999, SEMIN ONCOL, V26, P78
[7]  
Brinkschmidt C, 1997, J PATHOL, V181, P394
[8]   Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity [J].
Bulavin, DV ;
Demidov, ON ;
Saito, S ;
Kauraniemi, P ;
Phillips, C ;
Amundson, SA ;
Ambrosino, C ;
Sauter, G ;
Nebreda, AR ;
Anderson, CW ;
Kallioniemi, A ;
Fornace, AJ ;
Appella, E .
NATURE GENETICS, 2002, 31 (02) :210-215
[9]   Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones [J].
Clark, J ;
Edwards, S ;
John, M ;
Flohr, P ;
Gordon, T ;
Maillard, K ;
Giddings, I ;
Brown, C ;
Bagherzadeh, A ;
Campbell, C ;
Shipley, J ;
Wooster, R ;
Cooper, CS .
GENES CHROMOSOMES & CANCER, 2002, 34 (01) :104-114
[10]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648